Boundless Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Boundless Bio (BOLD).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

2Buy

2Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$8Upside to Avg. PT+229.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$5→$4
Jun 2, 2025	HC Wainwright & Co.	Mitchell Kapoor	Initiate	Buy	$5
May 28, 2025	Leerink Partners	Michael Cherny	Downgrade	Outperform→Market Perform	$15→$3
Dec 13, 2024	Guggenheim	Yige Guo	Downgrade	Buy→Neutral	—
Apr 22, 2024	Leerink Partners	Michael Cherny	Initiate	Outperform	$25
Apr 22, 2024	Guggenheim	Yige Guo	Initiate	Buy	$24
Apr 22, 2024	Piper Sandler	Joseph Catanzaro	Initiate	Overweight	$20

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $5

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and announces Price Target of $5.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3

Leerink Partners analyst Michael Cherny downgrades Boundless Bio (NASDAQ:BOLD) from Outperform to Market Perform and lowers the price target from $15 to $3.

Benzinga Newsdesk

PRO
Guggenheim Downgrades Boundless Bio to Neutral

Guggenheim analyst Yige Guo downgrades Boundless Bio (NASDAQ:BOLD) from Buy to Neutral.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25

Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24

Guggenheim analyst Yige Guo initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and announces Price Target of $24.

Benzinga Newsdesk

Boundless Bio Inc

Boundless Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4

PRO
HC Wainwright & Co. Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $5

PRO
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3

PRO
Guggenheim Downgrades Boundless Bio to Neutral

PRO
Leerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25

PRO
Guggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24

People Also Watch

People Also Watch

Boundless Bio Inc

Boundless Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4

PROHC Wainwright & Co. Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $5

PROLeerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3

PROGuggenheim Downgrades Boundless Bio to Neutral

PROLeerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25

PROGuggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4

PRO
HC Wainwright & Co. Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $5

PRO
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3

PRO
Guggenheim Downgrades Boundless Bio to Neutral

PRO
Leerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25

PRO
Guggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24